CNBC EN

FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share

The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.

Mar 19, 2026 &03531919202631; 16:53 UTC search.cnbc.com Trending 3/5

Read original on search.cnbc.com ↗

↗

Positive for markets

Sentiment score: +45/100

Moderate impact Short-term (days)

WHAT THIS MEANS

Rule-based L2: BULLISH signal from CNBC

AI CONFIDENCE

60% High

SENTIMENT GAUGE

NEWS POWER SCORE

⚡ SUGGESTED ACTION

Automated signal: BULLISH on primary asset

Analysis generated on Mar 21, 2026 at 15:37 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by CNBC. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share

RELATED INTELLIGENCE